このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

大うつ病性障害の治療におけるJNJ-89495120の有効性を探る研究 (Moonlight-1)

2026年9月24日 更新者:Janssen Research & Development, LLC

大うつ病性障害(MDD)の成人参加者における単独療法としてのJNJ-89495120の有効性、安全性、忍容性を評価するための無作為化、二重盲検、多施設共同、プラセボ対照の概念実証研究

The purpose of this study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on reducing the symptoms of depression in participants with major depressive disorder (MDD).

調査の概要

研究の種類

介入

入学 (実際)

105

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Alabama
      • Huntsville、Alabama、アメリカ、35801
        • UAB Huntsville Regional Medical Campus
    • Arizona
      • Chandler、Arizona、アメリカ、85224
        • Chandler Clinical Trials
      • Phoenix、Arizona、アメリカ、85012
        • IMA Clinical Research PC Phoenix
      • Tucson、Arizona、アメリカ、85724
        • University of Arizona
      • Tucson、Arizona、アメリカ、85704
        • Noble Clinical Research
    • California
      • Bellflower、California、アメリカ、90706
        • CI Trials
      • Encino、California、アメリカ、91316
        • Wake Research PRI Encino
      • Garden Grove、California、アメリカ、92844
        • National Institute Of Clinical Research
      • Newport Beach、California、アメリカ、92660
        • WR-Newport Beach
      • Orange、California、アメリカ、92866
        • ATP Clinical Research
      • Redlands、California、アメリカ、92374
        • Anderson Clinical Research
      • San Diego、California、アメリカ、92103
        • Artemis Institute for Clinical Research
      • San Jose、California、アメリカ、95124
        • Lumos Clinical Research Center LLC
      • Santa Ana、California、アメリカ、92705
        • Syrentis Clinical Research
      • Temecula、California、アメリカ、92591
        • Inland Psychiatric Medical Group Inc
      • Walnut Creek、California、アメリカ、94596
        • Sunwise Clinical Research
    • Colorado
      • Denver、Colorado、アメリカ、80209
        • Mountain View Clinical Research
    • Florida
      • Fort Myers、Florida、アメリカ、33912
        • Gulfcoast Medical Research Center
      • Hollywood、Florida、アメリカ、33021
        • The Medici Medical Research
      • Homestead、Florida、アメリカ、33030
        • Advanced Research Institute of Miami
      • Maitland、Florida、アメリカ、32751
        • K2 Medical Research
      • Miami、Florida、アメリカ、33126
        • Pharmax Research Clinic Inc
      • Miami、Florida、アメリカ、33135
        • Wellness Research Center
      • Pembroke Pines、Florida、アメリカ、33024
        • Best Choice Medical and Research Service
      • Tampa、Florida、アメリカ、33629
        • Interventional Psychiatry of Tampa Bay
      • West Palm Beach、Florida、アメリカ、33407
        • Health Synergy Clinical Research
    • Georgia
      • Atlanta、Georgia、アメリカ、30328
        • Synexus Clinical Research US Inc
      • Decatur、Georgia、アメリカ、30030
        • iResearch Atlanta LLC
      • Snellville、Georgia、アメリカ、30078
        • Accelerated Clinical Research Group LLC
    • Illinois
      • Chicago、Illinois、アメリカ、60637
        • University of Chicago Medical Center
    • Indiana
      • Indianapolis、Indiana、アメリカ、46202
        • Indiana University IU Health
    • Louisiana
      • New Orleans、Louisiana、アメリカ、70115
        • DelRicht Research
    • Maryland
      • Gaithersburg、Maryland、アメリカ、20877
        • CBH Health
    • Massachusetts
      • Worcester、Massachusetts、アメリカ、01655
        • University of Massachusetts Medical School
    • New York
      • Brooklyn、New York、アメリカ、11229
        • Integrative Clinical Trials LLC
    • Ohio
      • Cincinnati、Ohio、アメリカ、45219
        • University of Cincinnati
      • Cincinnati、Ohio、アメリカ、45215
        • Patient Priority Clinical Sites LLC
      • Columbus、Ohio、アメリカ、43210
        • OSU Department of Psychiatry and Behavioral Health
    • Oklahoma
      • Oklahoma City、Oklahoma、アメリカ、73116
        • Paradigm Research Professionals, LLC
    • Pennsylvania
      • Philadelphia、Pennsylvania、アメリカ、19104
        • University of Pennsylvania
    • South Carolina
      • North Charleston、South Carolina、アメリカ、29405
        • Coastal Carolina Research Center
    • Texas
      • McKinney、Texas、アメリカ、75071
        • Revival Research Institute LLC
    • Utah
      • Clinton、Utah、アメリカ、84015
        • Alpine Research Organization
    • Washington
      • Everett、Washington、アメリカ、98201
        • Core Clinical Research

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~64年 (大人)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Primary psychiatric diagnosis of recurrent major depressive disorder, without psychotic features, based on clinical assessment using diagnostic and statistical manual of mental disorders (DSM)-5 criteria and confirmed with the mini international neuropsychiatric interview (MINI)
  • Participant had to have at least one previous major depressive disorder (MDD) episode prior to their current episode
  • Were first diagnosed with depression before the age of 55
  • Are in a current episode of depression: Episode length must be at least 2 months but not longer than 24 months
  • Have taken 0, 1, or 2 treatments for depression in your current episode
  • Body mass index (BMI) within the range 18 to 35 kilograms per square meter (kg/m^2) at screening

Exclusion Criteria:

  • Treatment with vagus nerve stimulation (VNS), electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), deep brain stimulation (DBS), or ketamine/esketamine within the current or past major depressive episodes
  • Current or past DSM-5 diagnosis of bipolar disorder, psychotic disorders, borderline personality disorder, antisocial personality disorder, or current obsessive-compulsive disorder
  • Post-traumatic stress disorder within the past three years of screening
  • Dementia, any dementing disease, intellectual disability, or neurocognitive disorder
  • History of Alcohol and Substance use disorders within 6 months of screening, with the exclusion of nicotine, caffeine, and mild cannabis use disorder, according to the MINI and Clinical Assessment
  • Known allergies, hypersensitivity, or intolerance to JNJ-89495120 or its excipients

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
実験的:Arm 1: JNJ-89495120 Dose A

Participants will receive JNJ-89495120 dose A during the double-blind (DB) treatment phase in Period 1 and Period 2 of the study.

JNJ-89495120 will be administered.

実験的:Arm 2: JNJ-89495120 Dose A and Dose B

Participants will receive JNJ-89495120 dose A in Period 1 followed by JNJ-89495120 dose B in Period 2 during the DB treatment phase of the study.

JNJ-89495120 will be administered.

プラセボコンパレーター:Arm 3: Placebo Group

Participants will receive placebo matched to JNJ-89495120 during the DB treatment phase in Period 1 and Period 2 of the study.

Placebo will be administered.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score to Day 5
時間枠:Baseline up to Day 5

The MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.

Baseline up to Day 5

二次結果の測定

結果測定
メジャーの説明
時間枠
Change from Baseline in MADRS Total Score to Day 2
時間枠:Baseline up to Day 2

The MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.

Baseline up to Day 2
Change from Baseline in Clinician Global Impression-Severity (CGI-S) Scale Score to Days 2 and 5
時間枠:Baseline up to Day 2 and Day 5

The CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness. The CGI-S evaluates the severity of psychopathology on a scale of 1 to 7. Participant is assessed on severity of illness at the time of rating according to: 1=normal (not at all ill); 2=borderline ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill participants. Higher score indicating greater severity.

Baseline up to Day 2 and Day 5
Change from Baseline in Symptoms of Major Depressive Disorder Scale (SMDDS) Total Score to Day 5
時間枠:Baseline up to Day 5

The SMDDS is a 16-item patient reported outcome (PRO) measure. Each item is rated by the participant according to a 5-point Likert scale, where 0 denotes "Not at all" or "Never" and 4 denotes "Extremely" or "Always". Before summing the items to create a total score, item 11 and item 12 are combined into a single score by selecting the highest severity on either item. The total score is then created by summing the responses on the 15 items, which range from 0 to 60. Higher score indicates more severe depressive symptomatology.

Baseline up to Day 5
Change from Baseline in Generalized Anxiety Disorder-7 (GAD-7) Scale Score to Day 5
時間枠:Baseline up to Day 5

The GAD-7 scale is a self-administered questionnaire designed to measure anxiety. GAD-7 has seven items, which measure frequency of various signs of GAD using a 4-point Likert scale (where, Not at all = 0, Several days = 1, More than half the days = 2, and Nearly every day = 3). The total score ranges from 0 to 21 with increasing scores indicative of greater severity of symptoms of anxiety. Severity of anxiety on the GAD-7 is rated as follows: none (0-4), mild (5-9), moderate (10-14) and severe (15-21).

Baseline up to Day 5
Number of Participants with Adverse Events (AEs)
時間枠:Up to approximately 18 weeks

An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention.

Up to approximately 18 weeks
Number of Participants with Abnormalities in Vital Signs Parameters
時間枠:Up to approximately 18 weeks

Participants with abnormalities in vital signs (supine blood pressure, pulse/heart rate, respiratory rate, oral temperature) parameters will be reported.

Up to approximately 18 weeks
Number of Participants with 12-Lead Electrocardiogram (ECG) Abnormalities
時間枠:Up to approximately 18 weeks

Participants with 12-lead ECG abnormalities will be reported.

Up to approximately 18 weeks
Number of Participants With Abnormalities in Laboratory Parameters
時間枠:Up to approximately 18 weeks

Participants with abnormalities in clinical laboratory parameters (hematology and serum chemistry) will be reported.

Up to approximately 18 weeks
Number of Participants Reporting Changes in Weight/Body Mass Index (BMI)
時間枠:Up to approximately 18 weeks

Participants with changes in weight/BMI will be reported.

Up to approximately 18 weeks
Suicidal Ideation Assessment Using Columbia Suicide Severity Rating Scale (C-SSRS) Score
時間枠:Up to approximately 18 weeks

The C-SSRS scale consists of 28 items in 4 sections: suicide behavior, actual attempts, suicidal ideation, and intensity of ideation. Suicidal ideation consists of 5 'yes/no' items: wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods (not plan) without intention to act, active suicidal ideation with some intent to act without specific plan, active suicidal ideation with specific plan and intent. Only items with yes responses are listed. Worsening of suicidal ideation was an increase in severity of suicidal ideation from baseline.

Up to approximately 18 weeks
Change from Baseline in Cognitive Functioning Measured by the Hopkins Verbal Learning Test-Revised (HVLT-R)
時間枠:From Baseline up to 4 weeks

The HVLT-R, a measure of verbal learning and memory, is a 12-item word list recall test. Administration includes 3 learning trials, a delayed recall (20-minute) trial, and a 24-word recognition list (including 12 target and 12 foil words). The test administrator reads instructions and word lists aloud, and records words recalled/recognized by the participant. Three learning trials are combined to calculate a total recall score learning, delayed recall, and recognition trials.

From Baseline up to 4 weeks
Change from Baseline in Cognitive Functioning Measured by the Digit Symbol Substitution Test (DSST)
時間枠:From Baseline up to 4 weeks

The DSST is recognized as covering all of the cognitive performance aspects: speed of processing, executive functioning, and attention. The DSST measures attention, working memory, sustained visual attention and psychomotor speed. Participants are given a table that pairs digits and symbols, and asked to decipher a code using the table, completing as many as possible in 90 seconds.

From Baseline up to 4 weeks
Plasma Concentrations of JNJ-89495120
時間枠:Pre-dose (0 hours), and Post-dose on Days 1, 5 and 13

Plasma concentrations of JNJ-89495120 will be reported.

Pre-dose (0 hours), and Post-dose on Days 1, 5 and 13

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • スタディディレクター:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年12月26日

一次修了 (実際)

2026年6月25日

研究の完了 (実際)

2026年8月10日

試験登録日

最初に提出

2025年1月15日

QC基準を満たした最初の提出物

2025年1月15日

最初の投稿 (実際)

2025年1月20日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月25日

QC基準を満たした最後の更新が送信されました

2026年9月24日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 89495120MDD2001
  • 89495120MDD2001 (その他の識別子:Janssen Research & Development, LLC)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する